HER2-overexpressing and triple-negative subtypes depend on CPSF6 for viability and tumorigenic capacity in aggressive breast cancer cells of luminal B, and CPSF6 is overexpressed in human breast cancer cases, which is associated with poor prognosis [7]. Here, CPSF6 is linked to breast carcinoma.